A5042229648- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- PARP inhibition in cancer therapy
- Cancer, Lipids, and Metabolism
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- Multiple Myeloma Research and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Advanced Breast Cancer Therapies
- Bladder and Urothelial Cancer Treatments
- Pancreatic and Hepatic Oncology Research
- Hepatitis B Virus Studies
- Lung Cancer Research Studies
- Economic and Financial Impacts of Cancer
- Medical Imaging Techniques and Applications
- Colorectal and Anal Carcinomas
National Cancer Institute
2016-2025
National Institutes of Health
2016-2025
Center for Cancer Research
2017-2023
John Wiley & Sons (United States)
2018
Georgetown University Medical Center
2013-2018
Georgetown University
2013-2018
Cancer Institute (WIA)
2018
<h3>Background</h3> Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and approved by the U.S. Food Drug Administration locally advanced or metastatic urothelial advanced, unresectable stage 3 non-small cell lung cancer. Olaparib, poly (ADP-ribose) polymerase inhibitor, has demonstrated an improvement in median progression-free survival (PFS) select patients with...
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors such as veliparib are potent sensitizing agents and have been safely combined with DNA-damaging temozolomide. The effects of PARP magnified when cells harbor DNA repair defects.A single-arm, open-label, phase 2 study was performed to investigate the disease control rate (DCR) after cycles plus temozolomide in patients metastatic colorectal cancer (mCRC) refractory all standard therapies. Fifty received (150 mg/m2 /d) on days 1 5...
163 Background: Data suggests 25-30% of sporadic mCRPC has defects in DNA repair pathways which may confer sensitivity to PARP inhibition (PARPi). Immune checkpoint blockade increase the proportion patients that respond PARPi. We hypothesize increased damage by olaparib (O) will complement anti-tumor activity immune blocking antibody, durvalumab (D), (NCT02484404). Methods: Single arm pilot study with accrual 25 (pts) and disease is amenable biopsy. Prior treatment enzalutamide and/or...
Abstract Purpose: For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive therapy, many patients will have disease recurrence. Imaging has the potential to better define characteristics of response and resistance. In this study, we evaluated multiparametric MRI (mpMRI) before after neoadjuvant enzalutamide ADT. Patients Methods: Men with localized intermediate- cancer underwent a...
45 Background: PSMA imaging can identify recurrent prostate cancer after definitive surgery/radiation prior to detection on computed tomography (CT) or bone scan. Radiation PSMA+ findings is common but lacks clear data demonstrating long term benefit. (PSMArpc) often defined and treated as metastatic castration sensitive (mCSPC), yet alone an eligibility criteria was never studied in the mCSPC trials. PSMArpc requires better understanding define at-risk patients (pts). Methods: NCT05588128...
180 Background: BCR pts have a rising PSA after definitive surgery or radiation, but negative CT/Tc99 scans. While ADT-based strategies are commonly used, they can be associated with life-altering toxicities and not been shown to improve survival. Radium 223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover has demonstrated survival benefit metastatic prostate cancer, its benefits as monotherapy without ADT explored prior this study. This strategy may...
147 Background: The PARP inhibitor, ABT-888 is a potent sensitizing agent for, and has been safely combined with DNA-damaging chemotherapies. effects of are magnified when cancer cells harbor underlying defects in DNA repair mechanisms, such as BRCA2 mutations. Methods: We have initiated Phase I/II trial, we present here the data from I portion. Patients (pts) MPC who had any number prior therapies were eligible. A standard 3+3 dose escalation was employed, cohorts 40, 60, 80, 100, 150, 200,...
5026 Background: About 30% of sporadic mCRPC has defects in DNA repair pathways which may confer sensitivity to PARP inhibition. There is limited data about PDL1 inhibition mCRPC. We hypothesize increased damage by olaparib (O) will complement anti-tumor activity immune checkpoint blocking antibody, durvalumab (D), mCRPC:NCT02484404. Methods: Single arm pilot study with accrual 25 patients (pts) and biopsiable disease. Prior treatment enzalutamide and/or abiraterone required. D given at 1500...
162 Background: Recent data suggests 25-30% of sporadic mCRPC has defects in DNA repair pathways which may confer sensitivity to PARP inhibition. Immune checkpoint blockade is a promising avenue treatment. We hypothesize that increased damage by O will complement anti-tumor activity immune inhibitor, D, (NCT02484404). Methods: Eligible pts have with adequate end organ function and biopsiable disease (bone or soft tissue). Prior treatment enzalutamide and/or abiraterone required. D...
The standard treatment for non-metastatic castration sensitive prostate cancer (nmCSPC) is androgen deprivation therapy (ADT) or surveillance. This study evaluated the potential synergy of immunotherapy and enzalutamide (without ADT) in nmCSPC. In addition, immunologic impact was also men with normal testosterone.
3502 Background: Inhibitors of poly(ADP-ribose) polymerase (PARP), such as ABT-888 are potent sensitizing agents for, and have been safely combined with DNA-damaging chemotherapeutic temozolomide (TMZ). The effects PARP inhibitors magnified when cancer cells harbor underlying defects in DNA repair mechanisms. Methods: We performed a single arm, open label phase II study. Patients metastatic, unresectable colorectal (CRC) whose disease had progressed on all standard therapies were eligible....
Objective To evaluate the safety and efficacy of cabozantinib combined with docetaxel. Patients Methods This was a phase 1/2 multicentre study in patients metastatic castration‐resistant prostate cancer (mCRPC). Docetaxel (75 mg/m 2 every 3 weeks daily prednisone 10 mg) escalating doses (20, 40 60 mg). Based on results 1 study, investigation expanded into randomized docetaxel (hereafter 'docetaxel/prednisone') plus maximum tolerated dose (MTD) compared docetaxel/prednisone alone. Results A...
105 Background: Enzalutamideis ahighly effective treatment in patients with metastatic castration resistant prostate cancer (mCRPC). Although Prostate Cancer Working Group Guidelines (PCWG) recommend continuing until radiographic progression of disease (rPD) or clinical (cPD), many discontinue therapy for rising PSA alone. Methods: We conducted an open label, randomized phase 2 trial mCRPC (on testosterone suppression therapy) previously untreated docetaxel, abiraterone, enzalutamide,...
TPS170 Background: Inhibitors of Poly(ADP-ribose) polymerase (PARP) are potent sensitizing agents for DNA-damaging chemotherapeutic such as the platinum analogs. The effects PARP inhibitors magnified when cancer cells harbor defects in DNA repair enzymes including BRCA-2, FANCD2, PTEN, and mismatch proteins, occur often patients with pancreatic cancer. ABT-888 is a novel small molecule inhibitor that demonstrates inhibition, vivo, has synergistic anti-cancer activity combined oxaliplatin,...
214 Background: Enzalutamide (enz) is FDA approved for advanced prostate cancer, but studies are evaluating enz in earlier stages of disease. We have conducted a clinical trial (NCT01875250) ± therapeutic vaccine biochemically recurrent cancer. Methods: Eligible patients (pts) had PSA between 2.0-20.0 ng/ml, no metastatic disease and normal testosterone (T). Treatment all pts included 160 mg daily 84 days (D), T lowering therapy was permitted. This analysis evaluated the impact on regardless...
215 Background: Annually about 30-50,000 men are diagnosed with biochemically recurrent prostate cancer (BCRpc), defined by a rising PSA after radical prostatectomy (RP) or definitive radiation therapy (RT) negative conventional imaging (CT and bone scan). Standard treatments include salvage therapies, androgen deprivation surveillance. The role of immunotherapy in BCRpc is undefined. Methods: This study evaluates PROSTVAC, pox-viral based therapeutic vaccine targeting PSA, BCRpc. Key...
93 Background: M9241 is an immunocytokine that targets single- and double-stranded DNA which allows the treatment to localize IL-12 necrotic tumor (Xu, CCR 2017). was well-tolerated as a monotherapy in Phase I study with solid tumors (Strauss J, 2019). Additional preclinical data has demonstrated synergy of cytotoxic therapy. This first examine safety novel combination chemotherapy immunocytokines metastatic prostate cancer. Methods: analysis included patients mCSPC or mCRPC. Patients were...
241 Background: Docetaxel is a standard of care for mCSPC. Enzalutamide and abiraterone have been proven to improve survival in metastatic castration-resistant prostate cancer (mCRPC) patients. Little known about patients who treated with docetaxel mCSPC subsequent therapeutic responses. This retrospective analysis evaluate the response duration enzalutamide previously received but developed mCRPC within 12 months. Methods: Clinical Trial NCT02649855 enrolled newly diagnosed were androgen...
5104 Background: For patients that have a rising PSA and negative CT bone scan after surgery or radiation, there are no therapies been shown to improve survival. This fact has not changed by the approval of DCFPyL PET/CT PSMA, which can now define subclinical disease in with scans otherwise negative. Treatment outcome data BCR is equivalent metastatic castration sensitive prostate cancer (mCSPC). Despite lack for optimal management PSMA positive (ppBCR), many providers feel they must treat...
<h3>Background</h3> Prostate cancer (PC) is the most common non-cutaneous diagnosed among men in USA.<sup>1</sup> Although clinical outcomes are favorable for patients with localized disease, 20–30% of will develop metastatic prostate (mPC) and have poor prognosis. Immunotherapy, as a single agent, provides benefit to small subset PC patients, which thought be partially due its known cold tumor immune microenvironment (TIME). Combination studies needed enhance benefit.<sup>2</sup> Prostvac...
TPS5096 Background: Prostate cancer is the most commonly diagnosed among men in United States. While prostate initially responsive to androgen deprivation therapy (ADT), patients will develop castration-resistant disease. In past several years, despite multiple new therapeutics (docetaxel, abiraterone and enzalutamide) have been approved by FDA, majority become resistant treatments 2-3 years. Therefore, it necessary find metastatic (mCRPC). Methods: This phase II expansion cohort evaluate...
173 Background: A phase I study of Cabozantinib (C) in combination with docetaxel (D) and prednisone (P) patients (pts) mCRPC determined that 40 mg daily was the maximum tolerated dose C D P (C+DP). We report a pooled analysis randomized II comparing C+DP to DP alone. Methods: Eligible pts had without prior chemotherapy castrate setting. All received fixed (75 mg/m 2 IV day one each 21 cycle) (5 PO twice daily), group, at three escalating levels: 20 mg, or 60 cohort (all daily) cohort....